This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-16. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
== See also == Chinese herbology Ethnobotany Ethnomedicine Herbal Medicinal fungi List of plants used in herbalism Thomsonianism, a popular 19th century movement Traditional medicine Traditional Knowledge Digital Library
The dinoflagellates are yet another very large and diverse group, around half of which are at least partially photosynthetic (i.e. mixotrophic). Dinoflagellate chloroplasts have relatively complex history. Most dinoflagellate chloroplasts are secondary red algal derived chloroplasts. Many dinoflagellates have lost the chloroplast (becoming nonphotosynthetic), some of these have replaced it though tertiary endosymbiosis. Others replaced their original chloroplast with a green algal derived chloroplast. The peridinin chloroplast is thought to be the dinophytes' "original" chloroplast, which has been lost, reduced, replaced, or has company in several other dinophyte lineages. The most common dinophyte chloroplast is the peridinin-type chloroplast, characterized by the carotenoid pigment peridinin in their chloroplasts, along with chlorophyll a and chlorophyll c2. Peridinin is not found in any other group of chloroplasts. The peridinin chloroplast is bounded by three membranes (occasionally two), having lost the red algal endosymbiont's original cell membrane. The outermost membrane is not connected to the endoplasmic reticulum. They contain a pyrenoid, and have triplet-stacked thylakoids. Starch is found outside the chloroplast. Peridinin chloroplasts also have DNA that is highly reduced and fragmented into many small circles. Most of the genome has migrated to the nucleus, and only critical photosynthesis-related genes remain in the chloroplast.
In the 19th century, fueled by nationalism, both Danes and Germans claimed Schleswig-Holstein. The Germans wanted both Schleswig and Holstein to separate from Denmark and join the German Confederation, invoking the Treaty of Ribe stating that the two duchies should stay "Forever Undivided". The Danes, on the other hand, furthered the Eider Policy (da:Ejderpolitikken), stating that the natural Danish border was the Eider (river) as first recognised in the Treaty of Heiligen. Therefore, the Danes sought to reintegrate Schleswig into the Kingdom of Denmark, reversing the separation created by King Abel, while also granting Holstein independence to join the German Confederation as a sovereign entity. The resulting long-term political and territorial dispute was known as the Schleswig-Holstein Question. Holstein was entirely German-speaking, while Schleswig was predominantly Danish-speaking until the late 1700s and early 1800s. During this period, a linguistic shift began in southern Schleswig, transitioning from Danish to German. This meant that Schleswig was linguistically divided with a Danish-speaking north and a German-speaking south. In 1848, King Frederick VII of Denmark declared that he would grant Denmark a liberal constitution and the immediate goal of the Danish national movement was to ensure that this constitution would give rights to all Danes, i.e. not only to those in the Kingdom of Denmark, but also to Danes (and Germans) living in Schleswig.
Sources: en.wikipedia.org
=== 3 May === The SAF said that the RSF fired several suicide drones towards Kassala Airport and Port Sudan, targeting Port Sudan Air Base and a goods warehouse and civilian facilities in the city, causing "limited damage". The SAF launched airstrikes on Nyala Airport following the landing of an aircraft believed to be transporting weapons to the RSF. The leader of the Otash IDP camp in Nyala, Abdel Razek Hassan Jalis, was shot dead along with his son and another camp resident in an attack by the RSF.
=== Inflammation === CCN1 promotes the apoptotic functions of inflammatory cytokines such as TNFα, FasL, and TRAIL. It also reprograms macrophages towards M1 polarization through αMβ2-mediated activation of NF-κB. CCN1 is upregulated in patients with Crohn's disease and ulcerative colitis. CCN1 supports the patrolling behavior of murine resident Ly6Clow monocytes along the endothelial in the steady state and is required for their accumulation under viral-mimicking vascular inflammation.
Organised retail will need workers. Walmart employs 1.4 million people in United States alone. With United States population of about 300 million, and India's population of about 1200 million, if Walmart-like retail companies were to expand in India as much as their presence in the United States, and the staffing level in Indian stores kept at the same level as in the United States stores, Walmart alone would employ 5.6 million Indian citizens. Walmart has a 6.5% market share of the total United States retail. Adjusted for this market share, the expected jobs in future Indian organised retail would total over 85 million. In addition, millions of additional jobs will be created during the building of and the maintenance of retail stores, roads, cold storage centers, software industry, electronic cash registers and other retail supporting organisations. Instead of job losses, retail reforms are likely to be massive boost to Indian job availability. KPMG - one of the world's largest audit companies - finds that in China, the employment in both retail and wholesale trade increased from 4% in 1992 to about 7% in 2001, post China opening its retail to foreign and domestic innovation and competition. In absolute terms, China experienced the creation of 26 million new jobs within 9 years, post China announcing FDI retail reforms. Additionally, contrary to some concerns in China, post retail reforms, the number of traditional small retailers also grew by 30% over 5 years.
Sources: en.wikipedia.org
=== Lily Tao === Lily Tao (played by an uncredited child actress in series 1, Neve Bonner in series 2-3, and Serrana Su-Ling Bliss in series 4) is one of Eric and Candice's daughters, alongside her twin sister Lara. In series 1, Harper spots Eric playing with his daughters in a grocery store after being suspended from Pierpoint. In series 2, Eric returns home from a trip to New York to kiss his children goodnight, having secretly cheated on their mother with his ex-girlfriend Holly during the trip. In series 3, Eric, divorced from Candice, brings his daughters to Pierpoint on the day of the tumultuous IPO of green-energy company Lumi. In series 4, Lily is older and attending private school in England, while Eric is retired and living in the United States, estranged from his family. His family office, LilyLara, is named after his daughters. Eric returns to London to partner with Harper on a short-only hedge fund, SternTao, and allows Lily to visit the hotel serving as their office, blurring the work-life boundary Harper strives to maintain with Eric. Eric later learns Lily has been expelled from school for running a catfishing scheme on another student, and reflects on how his daughter has inherited his own cruelty, while lamenting his own inability to properly love his children. He comforts Lily and allows her and Candice to stay in his suite, but visits a prostitute that same night.
=== Beer–Lambert law === The roots of the term absorbance are in the Beer–Lambert law (or Beer's law). As light moves through a medium, it will become dimmer as it is being "extinguished". Pierre Bouguer recognized that this extinction (now often called attenuation) was not linear with distance traveled through the medium, but related to what is now referred to as an exponential function. If
adenosine triphosphate (ATP) A nucleoside triphosphate consisting of adenosine attached to three consecutive phosphate groups via high-energy ester bonds. The conversion of ATP into ADP or AMP via hydrolysis of these phosphates releases energy which is used to drive the majority of energy-consuming chemical reactions in all living cells, and hence ATP functions as a universal and ubiquitous energy carrier which is often referred to as the "molecular currency" of intracellular metabolism. It is continuously regenerated via phosphorylation of ADP and AMP by enzymes such as ATP synthase. Like other nucleoside triphosphates, it also serves as a precursor for nucleic acid synthesis.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.